You're contacting media contact of this press release

Title: Pfizer Inc. Announces $150,000 Research Grant to Peptos Protocol for Advancement of AI-Driven Peptide Research and Development

United States, 6th May 2026 – Pfizer Inc. (NYSE: PFE) today announced a strategic research grant of $150,000 to Peptos Protocol, an innovative cryptocurrency project leveraging artificial intelligence for peptide research and development. This grant represents Pfizer's continued commitment to exploring cutting-edge technologies that could accelerate therapeutic discovery and development processes.The collaboration will focus on advancing Peptos Protocol's proprietary AI-powered platform designed to streamline peptide identification, optimization, and synthesis prediction. Peptide therapeutics represent a rapidly growing segment in pharmaceutical development, with potential applications across numerous disease areas including metabolic disorders, oncology, and infectious diseases. More information about Peptos Protocol's innovative approach can be found at their official website, peptos.bio."As a company dedicated to breakthroughs that change patients' lives, Pfizer recognizes the transformative potential of combining artificial intelligence with peptide science," said Dr. Michael Harrington, Vice President of Emerging Research Technologies at Pfizer. "This grant to Peptos Protocol aligns with our strategic interest in exploring novel computational approaches that could potentially reduce development timelines and increase success rates in early-stage therapeutic discovery."Peptos Protocol's blockchain-based platform utilizes machine learning algorithms to predict peptide structures with enhanced binding affinity, stability, and therapeutic potential. The decentralized nature of the platform allows researchers worldwide to contribute to and benefit from shared computational resources and data insights. The technical specifications of their groundbreaking platfo...

This press release is issued by King Newswire